This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

oxycodone (OxyNorm Dispersa®)

Reference No. 1981

Publication date:

Appraisal information

oxycodone (OxyNorm Dispersa®) 5 mg orodispersible tablet
oxycodone (OxyNorm Dispersa®) 10 mg orodispersible tablet
oxycodone (OxyNorm Dispersa®) 20 mg orodispersible tablet

Company: Napp Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 22/05/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, oxycodone orodispersible tablets (OxyNorm Dispersa®) cannot be endorsed for use within NHS Wales for the treatment of moderate to severe pain in patients with cancer and postoperative pain and treatment of severe pain requiring the use of a strong opioid.
Statement of Advice (SOA)